What is Diopsys?
Diopsys is a specialized medical technology firm focused on the development and commercialization of advanced vision testing systems. Its flagship offering, the NOVA Vision Testing System, provides clinicians with objective data through Visual Evoked Potential (VEP) and Electroretinography (ERG) technologies. By bridging the gap between subjective patient reporting and objective physiological measurement, Diopsys enables healthcare providers to make more informed diagnostic decisions. The company maintains a robust presence in the United States, while simultaneously expanding its international footprint to address the growing demand for high-precision ocular diagnostics in diverse clinical environments.
How much funding has Diopsys raised?
Diopsys has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in Diopsys
PPP
Public-Private Partnership
What's next for Diopsys?
Following this major strategic investment, Diopsys is well-positioned to accelerate its research and development initiatives and expand its market reach. The company is expected to leverage this capital to refine its diagnostic algorithms and potentially broaden the regulatory approval scope for its ERG technology in domestic markets. As the healthcare industry shifts toward data-driven, objective diagnostic standards, Diopsys remains a critical player in the evolution of vision care. Future strategic milestones will likely focus on scaling commercial operations and integrating its diagnostic suite into broader electronic health record ecosystems to enhance clinical workflow efficiency.
See full Diopsys company page
